Relation between anticholinergic burden and cognitive impairment: Results from the Monzino 80‐plus population‐based study. Issue 12 (3rd November 2020)

• Record Type: Journal Article
• Authors: Pasina, Luca; Lucca, Ugo; Tettamanti, Mauro
• Is Part Of: Pharmacoepidemiology and drug safety. Volume 29:Issue 12(2020)
• Page Start: 1696
• Page End: 1702
• Publication Date: 2020-11-03
• Subjects: anticholinergic burden -- cognitive performance -- dementia -- oldest‐old -- pharmacoepidemiology; Pharmacoepidemiology -- Periodicals; Chemotherapy -- Periodicals; Epidemiology -- Periodicals; 615.705
• DOI: 10.1002/pds.5159
• Languages: English
• ISSNs: 1053-8569

Abstract

Abstract: Purpose: We examined data collected in the Monzino 80‐plus study to assess the relations between cognitive performance and ACB scores according to the hypothesis that a higher anticholinergic burden is associated with reduced cognitive performance. Methods: The Monzino 80‐plus is an ongoing, prospective, door‐to‐door population‐based study started in 2002 among all residents 80 years or older in eight municipalities of Varese province, Italy. To establish the relation between cognitive impairment and the anticholinergic drug burden we recorded the ACB score for each patient at baseline. The relations between ACB score and dementia or MMSE scores were also examined after exclusion of patients taking any antipsychotic. Results: A sample of 2140 elderly people was eligible for analysis. A significant dose‐effect relationship was observed between total ACB score and diagnosis of dementia in univariate and multivariate models. Patients in ACB class ≥4 had about 4.5 times the risk of diagnosis of dementia. A relation was also found between higher ACB scores and lower MMSE scores; patients who scored 4 or more had a mean of 6.4 points lower than those not taking anticholinergic drugs. The dose‐effect relationship between ACB score and diagnosis of dementia was not maintained after exclusion of patients using antipsychotics, while the association between higher ACB scores and lower MMSE scores was still present, with patients in ACB class ≥4 having a mean score about 4.4 lower. Conclusions: There are clear relations between anticholinergic load and reduced cognitive performance, while the association with dementia remains uncertain. For primary care and geriatric clinicians, an ACB score ≥ 4 can be considered the cut‐off to identify high‐risk populations who may benefit from the evaluation of anticholinergic burden with the ACB scale.